Bone marrow mesenchymal stem cells-derived exosomal microRNA-124-3p attenuates hypoxic-ischemic brain damage through depressing tumor necrosis factor receptor associated factor 6 in newborn rats

Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in hypoxic-ischemic brain damage (HIBD) is not completely comprehended. Thereupon, this work was put forward to reveal the action of bone marrow...

Full description

Saved in:
Bibliographic Details
Published inBioengineered Vol. 13; no. 2; pp. 3195 - 3207
Main Authors Min, Weijie, Wu, Yina, Fang, Yibin, Hong, Bo, Dai, Dongwei, Zhou, Yu, Liu, Jianmin, Li, Qiang
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.02.2022
Subjects
Animals
Bone Marrow Cells - metabolism
bone marrow mesenchymal stem cells
Brain Injuries - metabolism
Brain Injuries - therapy
Brain Ischemia - metabolism
Brain Ischemia - therapy
exosomes
Exosomes - metabolism
Exosomes - transplantation
Hypoxic-ischemic brain damage
Male
Mesenchymal Stem Cells - metabolism
MicroRNA-124-3p
MicroRNAs - metabolism
Rats
Rats, Sprague-Dawley
Research Paper
TNF Receptor-Associated Factor 6 - metabolism
tumor necrosis factor receptor associated factor 6
MicroRNA-124-3p
bone marrow mesenchymal stem cells
Hypoxic-ischemic brain damage
exosomes
tumor necrosis factor receptor associated factor 6
Online AccessGet full text

Cover

Abstract Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in hypoxic-ischemic brain damage (HIBD) is not completely comprehended. Thereupon, this work was put forward to reveal the action of bone marrow MSCs-derived Exo (BMSCs-Exo) expressing miR-124-3p in the illness. BMSCs were isolated and transfected with miR-124-3p agomir. Then, BMSCs-Exo were extracted and identified. The newborn HIBD rats were injected with miR-124-3p-modified BMSCs-Exo or tumor necrosis factor receptor associated factor 6 (TRAF6)-related vectors. Next, neurological functions, neuron pathological and structural damages, oxidative stress and neuronal apoptosis were observed. miR-124-3p and TRAF6 expression was tested, along with their targeting relationship. miR-124-3p was down-regulated, and TRAF6 was up-regulated in newborn HIBD rats. miR-124-3p targeted TRAF6. BMSCs-Exo improved neurological functions, alleviated neuron pathological and structural damages, suppressed oxidative stress and reduced neuronal apoptosis in newborn HIBD rats, whereas BMSCs-Exo-mediated effects were enhanced by restoring miR-124-3p. Silencing TRAF6 attenuated HIBD in newborn rats, but overexpression of TRAF6 reversed the protective role of miR-124-3p-overexpressing BMSCs-Exo. This work makes it comprehensive that up-regulated exosomal miR-124-3p ameliorates HIBD in newborn rats by targeting TRAF6, which replenishes the potential agents for curing HIBD.
AbstractList Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in hypoxic-ischemic brain damage (HIBD) is not completely comprehended. Thereupon, this work was put forward to reveal the action of bone marrow MSCs-derived Exo (BMSCs-Exo) expressing miR-124-3p in the illness. BMSCs were isolated and transfected with miR-124-3p agomir. Then, BMSCs-Exo were extracted and identified. The newborn HIBD rats were injected with miR-124-3p-modified BMSCs-Exo or tumor necrosis factor receptor associated factor 6 (TRAF6)-related vectors. Next, neurological functions, neuron pathological and structural damages, oxidative stress and neuronal apoptosis were observed. miR-124-3p and TRAF6 expression was tested, along with their targeting relationship. miR-124-3p was down-regulated, and TRAF6 was up-regulated in newborn HIBD rats. miR-124-3p targeted TRAF6. BMSCs-Exo improved neurological functions, alleviated neuron pathological and structural damages, suppressed oxidative stress and reduced neuronal apoptosis in newborn HIBD rats, whereas BMSCs-Exo-mediated effects were enhanced by restoring miR-124-3p. Silencing TRAF6 attenuated HIBD in newborn rats, but overexpression of TRAF6 reversed the protective role of miR-124-3p-overexpressing BMSCs-Exo. This work makes it comprehensive that up-regulated exosomal miR-124-3p ameliorates HIBD in newborn rats by targeting TRAF6, which replenishes the potential agents for curing HIBD.
Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in hypoxic-ischemic brain damage (HIBD) is not completely comprehended. Thereupon, this work was put forward to reveal the action of bone marrow MSCs-derived Exo (BMSCs-Exo) expressing miR-124-3p in the illness. BMSCs were isolated and transfected with miR-124-3p agomir. Then, BMSCs-Exo were extracted and identified. The newborn HIBD rats were injected with miR-124-3p-modified BMSCs-Exo or tumor necrosis factor receptor associated factor 6 (TRAF6)-related vectors. Next, neurological functions, neuron pathological and structural damages, oxidative stress and neuronal apoptosis were observed. miR-124-3p and TRAF6 expression was tested, along with their targeting relationship. miR-124-3p was down-regulated, and TRAF6 was up-regulated in newborn HIBD rats. miR-124-3p targeted TRAF6. BMSCs-Exo improved neurological functions, alleviated neuron pathological and structural damages, suppressed oxidative stress and reduced neuronal apoptosis in newborn HIBD rats, whereas BMSCs-Exo-mediated effects were enhanced by restoring miR-124-3p. Silencing TRAF6 attenuated HIBD in newborn rats, but overexpression of TRAF6 reversed the protective role of miR-124-3p-overexpressing BMSCs-Exo. This work makes it comprehensive that up-regulated exosomal miR-124-3p ameliorates HIBD in newborn rats by targeting TRAF6, which replenishes the potential agents for curing HIBD.Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in hypoxic-ischemic brain damage (HIBD) is not completely comprehended. Thereupon, this work was put forward to reveal the action of bone marrow MSCs-derived Exo (BMSCs-Exo) expressing miR-124-3p in the illness. BMSCs were isolated and transfected with miR-124-3p agomir. Then, BMSCs-Exo were extracted and identified. The newborn HIBD rats were injected with miR-124-3p-modified BMSCs-Exo or tumor necrosis factor receptor associated factor 6 (TRAF6)-related vectors. Next, neurological functions, neuron pathological and structural damages, oxidative stress and neuronal apoptosis were observed. miR-124-3p and TRAF6 expression was tested, along with their targeting relationship. miR-124-3p was down-regulated, and TRAF6 was up-regulated in newborn HIBD rats. miR-124-3p targeted TRAF6. BMSCs-Exo improved neurological functions, alleviated neuron pathological and structural damages, suppressed oxidative stress and reduced neuronal apoptosis in newborn HIBD rats, whereas BMSCs-Exo-mediated effects were enhanced by restoring miR-124-3p. Silencing TRAF6 attenuated HIBD in newborn rats, but overexpression of TRAF6 reversed the protective role of miR-124-3p-overexpressing BMSCs-Exo. This work makes it comprehensive that up-regulated exosomal miR-124-3p ameliorates HIBD in newborn rats by targeting TRAF6, which replenishes the potential agents for curing HIBD.
Author Li, Qiang
Liu, Jianmin
Min, Weijie
Wu, Yina
Zhou, Yu
Dai, Dongwei
Hong, Bo
Fang, Yibin
Author_xml – sequence: 1
  givenname: Weijie
  surname: Min
  fullname: Min, Weijie
– sequence: 2
  givenname: Yina
  surname: Wu
  fullname: Wu, Yina
– sequence: 3
  givenname: Yibin
  surname: Fang
  fullname: Fang, Yibin
– sequence: 4
  givenname: Bo
  surname: Hong
  fullname: Hong, Bo
  organization: Changhai Stroke Center, Changhai Hospital, Second Military Medical University
– sequence: 5
  givenname: Dongwei
  surname: Dai
  fullname: Dai, Dongwei
  organization: Changhai Stroke Center, Changhai Hospital, Second Military Medical University
– sequence: 6
  givenname: Yu
  surname: Zhou
  fullname: Zhou, Yu
  organization: Changhai Stroke Center, Changhai Hospital, Second Military Medical University
– sequence: 7
  givenname: Jianmin
  surname: Liu
  fullname: Liu, Jianmin
  email: Liujianmin1999@163.com
  organization: Changhai Stroke Center, Changhai Hospital, Second Military Medical University
– sequence: 8
  givenname: Qiang
  surname: Li
  fullname: Li, Qiang
  email: Liqiang19991@outlook.com
  organization: Changhai Stroke Center, Changhai Hospital, Second Military Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35067167$$D View this record in MEDLINE/PubMed
BookMark eNqFUl2P1SAUbMwad133J2h49KUrlEJpTIzrxlWTjSZGnwmXHm4xLVSge_f-PX_Z0tyPqA_6AgfOzBwyzNPixHkHRfGc4EuCBX5VEc5Y27SXFa5IXgjHbf2oOFvuS9aK5uRYN-1pcRHjD4wxwbRmjXhSnFKGeUN4c1b8epeV0ahC8Bs0QgSn--2oBhQTjEjDMMSyg2DvoENw76NfeqPVwX_9fFWSqi7phFRK4GaVIKJ-O_l7q0sbdQ8Zh1ZBWYc6Nao1oNQHP6971MEUIEbr1ijNow_IQVaMNiKjdMrnABqmpVAxem2zdHdocZT1HGxWPjgUVIrPisdGDREu9vt58f3m_bfrj-Xtlw-frq9uS11zkUplDCeM0E7oxnRGrBRXQmtuVkZopkFgzBrctIxDXdVUiwoLQwnlmJi6aik9L97sdKd5NUKnwaWgBjkFm-3bSq-s_LPjbC_X_k6KtqEtFVng5V4g-J8zxCTHbFO2WDnwc5QVr6pakLplGfri91nHIYePywC2Ayy-xQDmCCFYLhmRh4zIJSNyn5HMe_0XT9ukkvXLk-3wX_bbHds648OoNj4MnUxqO_hggnLaRkn_LfEAmj_aLA
CitedBy_id crossref_primary_10_3390_cells11223623
crossref_primary_10_1007_s11064_022_03752_4
crossref_primary_10_1080_10799893_2024_2303014
crossref_primary_10_1007_s11011_022_00997_4
crossref_primary_10_1016_j_lfs_2023_121566
crossref_primary_10_1016_j_ijbiomac_2023_124932
crossref_primary_10_3390_ijms24032622
crossref_primary_10_1002_btpr_3383
crossref_primary_10_2147_IJN_S407029
crossref_primary_10_1007_s12035_024_04507_8
crossref_primary_10_1002_nep3_30
crossref_primary_10_1007_s12035_024_03957_4
crossref_primary_10_1186_s40779_024_00540_9
crossref_primary_10_1002_jex2_156
crossref_primary_10_1002_mco2_287
crossref_primary_10_1007_s10571_023_01345_5
Cites_doi 10.1007/s10495-020-01596-3
10.1097/WNR.0000000000001559
10.1016/j.biopha.2019.108818
10.1097/WNR.0000000000001194
10.3892/or.2015.4109
10.1016/j.expneurol.2018.05.013
10.7150/ijbs.14809
10.1111/j.1442-200X.2010.03290.x
10.1007/978-1-4939-7172-5_15
10.1155/2020/8869511
10.1016/j.brainresbull.2020.08.006
10.1021/acs.molpharmaceut.0c00195
10.1016/j.jss.2014.02.034
10.1016/j.expneurol.2019.03.017
10.1007/s11011-019-0393-9
10.1007/s00018-018-2911-z
10.1007/s10571-019-00769-2
10.1007/s10753-016-0384-5
10.1177/0960327119897103
10.1016/j.gendis.2019.01.002
10.1186/s13075-020-2146-x
10.1186/s12868-020-00565-5
10.1016/j.expneurol.2021.113700
10.1161/STROKEAHA.116.015753
10.1016/j.brainresbull.2019.06.004
10.1016/0952-0600(92)90018-C
10.1111/bph.13270
10.1155/2021/8884438
10.1016/j.cellsig.2019.109436
10.5966/sctm.2015-0197
10.1016/j.omtn.2017.04.010
10.1016/j.biopha.2017.06.051
10.1096/fj.201700673r
10.1038/s41598-017-00629-3
10.3390/cells8080855
10.1007/s11064-020-02998-0
10.2147/DDDT.S178698
10.1016/j.jconrel.2017.08.022
10.2174/1381612825666190119130441
10.1007/s10863-019-09812-9
10.33594/000000090
10.2174/1570159X16666180412094655
10.1007/s12031-020-01483-1
10.1523/JNEUROSCI.1751-17.2017
ContentType Journal Article
Copyright 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
Copyright_xml – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022
– notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1080/21655979.2021.2016094
DatabaseName Taylor & Francis Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Free Journals (Free resource, activated by CARLI)
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
DocumentTitleAlternate W. MIN ET AL
EISSN 2165-5987
EndPage 3207
ExternalDocumentID PMC8973938
35067167
10_1080_21655979_2021_2016094
2016094
Genre Research Article
Video-Audio Media
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 0YH
4.4
53G
ABCCY
ABPEM
ACGFS
ADBBV
ADCVX
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BCNDV
DGEBU
EBS
EMOBN
GROUPED_DOAJ
GTTXZ
H13
IPNFZ
M4Z
OK1
RIG
RPM
SV3
TDBHL
TFL
TFW
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
EJD
HYE
NPM
OVD
TEORI
TTHFI
7X8
5PM
ID FETCH-LOGICAL-c468t-aff61513d8c7fdf8ba6a8cc6fbf8c5ce8005707956e4243c8208f313601f42933
IEDL.DBID 0YH
ISSN 2165-5979
2165-5987
IngestDate Thu Aug 21 14:00:53 EDT 2025
Thu Jul 10 18:06:49 EDT 2025
Thu Jan 02 22:55:47 EST 2025
Thu Apr 24 22:58:11 EDT 2025
Tue Jul 01 03:52:52 EDT 2025
Wed Dec 25 09:04:44 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords MicroRNA-124-3p
bone marrow mesenchymal stem cells
Hypoxic-ischemic brain damage
exosomes
tumor necrosis factor receptor associated factor 6
Language English
License open-access: http://creativecommons.org/licenses/by-nc/4.0/: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-aff61513d8c7fdf8ba6a8cc6fbf8c5ce8005707956e4243c8208f313601f42933
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
These authors are co-first authors.
These authors are co-corresponding authors.
OpenAccessLink https://www.tandfonline.com/doi/abs/10.1080/21655979.2021.2016094
PMID 35067167
PQID 2622481495
PQPubID 23479
PageCount 13
ParticipantIDs informaworld_taylorfrancis_310_1080_21655979_2021_2016094
pubmed_primary_35067167
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8973938
crossref_primary_10_1080_21655979_2021_2016094
proquest_miscellaneous_2622481495
crossref_citationtrail_10_1080_21655979_2021_2016094
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-01
PublicationDateYYYYMMDD 2022-02-01
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Bioengineered
PublicationTitleAlternate Bioengineered
PublicationYear 2022
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References cit0011
cit0033
cit0012
cit0034
cit0031
cit0010
cit0030
Zhu L (cit0032) 2020; 22
Yang L (cit0003) 2020; 35
cit0019
cit0017
cit0039
cit0018
cit0015
cit0037
cit0016
cit0038
cit0013
cit0035
cit0014
cit0036
cit0022
cit0044
cit0001
cit0023
cit0045
cit0020
cit0042
cit0043
cit0040
Xiao B (cit0021) 2019; 8
cit0041
cit0008
cit0009
cit0006
cit0028
cit0007
cit0029
cit0004
cit0026
cit0005
cit0027
cit0002
cit0024
cit0046
cit0025
cit0047
References_xml – ident: cit0036
  doi: 10.1007/s10495-020-01596-3
– ident: cit0013
  doi: 10.1097/WNR.0000000000001559
– ident: cit0023
  doi: 10.1016/j.biopha.2019.108818
– ident: cit0001
  doi: 10.1097/WNR.0000000000001194
– ident: cit0019
  doi: 10.3892/or.2015.4109
– ident: cit0015
  doi: 10.1016/j.expneurol.2018.05.013
– ident: cit0020
  doi: 10.7150/ijbs.14809
– ident: cit0002
  doi: 10.1111/j.1442-200X.2010.03290.x
– ident: cit0033
  doi: 10.1007/978-1-4939-7172-5_15
– ident: cit0043
  doi: 10.1155/2020/8869511
– ident: cit0025
  doi: 10.1016/j.brainresbull.2020.08.006
– ident: cit0005
  doi: 10.1021/acs.molpharmaceut.0c00195
– ident: cit0028
  doi: 10.1016/j.jss.2014.02.034
– ident: cit0027
  doi: 10.1016/j.expneurol.2019.03.017
– ident: cit0035
  doi: 10.1007/s11011-019-0393-9
– ident: cit0044
  doi: 10.1007/s00018-018-2911-z
– ident: cit0009
  doi: 10.1007/s10571-019-00769-2
– ident: cit0046
  doi: 10.1007/s10753-016-0384-5
– ident: cit0031
  doi: 10.1177/0960327119897103
– ident: cit0011
  doi: 10.1016/j.gendis.2019.01.002
– ident: cit0010
  doi: 10.1186/s13075-020-2146-x
– ident: cit0004
  doi: 10.1186/s12868-020-00565-5
– ident: cit0040
  doi: 10.1016/j.expneurol.2021.113700
– ident: cit0026
  doi: 10.1161/STROKEAHA.116.015753
– ident: cit0024
  doi: 10.1016/j.brainresbull.2019.06.004
– volume: 22
  start-page: 3944
  issue: 5
  year: 2020
  ident: cit0032
  publication-title: Mol Med Rep
– ident: cit0029
  doi: 10.1016/0952-0600(92)90018-C
– ident: cit0047
  doi: 10.1111/bph.13270
– ident: cit0012
  doi: 10.1155/2021/8884438
– ident: cit0017
  doi: 10.1016/j.cellsig.2019.109436
– ident: cit0007
  doi: 10.5966/sctm.2015-0197
– ident: cit0008
  doi: 10.1016/j.omtn.2017.04.010
– ident: cit0034
  doi: 10.1016/j.biopha.2017.06.051
– ident: cit0045
  doi: 10.1096/fj.201700673r
– ident: cit0030
  doi: 10.1038/s41598-017-00629-3
– ident: cit0039
  doi: 10.3390/cells8080855
– ident: cit0038
  doi: 10.1007/s11064-020-02998-0
– ident: cit0018
  doi: 10.2147/DDDT.S178698
– volume: 8
  start-page: 1
  issue: 5
  year: 2019
  ident: cit0021
  publication-title: Biol Open
– ident: cit0022
  doi: 10.1016/j.jconrel.2017.08.022
– ident: cit0037
  doi: 10.2174/1381612825666190119130441
– ident: cit0042
  doi: 10.1007/s10863-019-09812-9
– volume: 35
  start-page: 929
  issue: 9
  year: 2020
  ident: cit0003
  publication-title: Histol Histopathol
– ident: cit0006
  doi: 10.33594/000000090
– ident: cit0014
  doi: 10.2174/1570159X16666180412094655
– ident: cit0041
  doi: 10.1007/s12031-020-01483-1
– ident: cit0016
  doi: 10.1523/JNEUROSCI.1751-17.2017
SSID ssj0001034578
Score 2.3371985
Snippet Mesenchymal stem cells (MSCs)-derived exosomes (Exo) are beneficial in the use of brain damages. Restrictively, the mechanism of Exo expressing miR-124-3p in...
SourceID pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3195
SubjectTerms Animals
Bone Marrow Cells - metabolism
bone marrow mesenchymal stem cells
Brain Injuries - metabolism
Brain Injuries - therapy
Brain Ischemia - metabolism
Brain Ischemia - therapy
exosomes
Exosomes - metabolism
Exosomes - transplantation
Hypoxic-ischemic brain damage
Male
Mesenchymal Stem Cells - metabolism
MicroRNA-124-3p
MicroRNAs - metabolism
Rats
Rats, Sprague-Dawley
Research Paper
TNF Receptor-Associated Factor 6 - metabolism
tumor necrosis factor receptor associated factor 6
Title Bone marrow mesenchymal stem cells-derived exosomal microRNA-124-3p attenuates hypoxic-ischemic brain damage through depressing tumor necrosis factor receptor associated factor 6 in newborn rats
URI https://www.tandfonline.com/doi/abs/10.1080/21655979.2021.2016094
https://www.ncbi.nlm.nih.gov/pubmed/35067167
https://www.proquest.com/docview/2622481495
https://pubmed.ncbi.nlm.nih.gov/PMC8973938
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgucAB8aa8ZCSuhsR2HOe4IFYVEntArASnyE9aiSTVJkW7f49fxkzilBaB9sAtkjNJ2vlsf2PNfEPIK-FDdFnUTMpSMGmqktngMxa4dMp75_IC650_nqrlmfzwpZizCfuUVokxdJyEIsa1Gie3sf2cEfeG5wp5MJaZcAzxcgUxynVygyNaAdLZ1-XvY5ZMyGJcj9GKodlcx_OvJx3sUAf6pX9joX8mU-7tTid3yO1EK-nxhIO75Fpo75Fbe2KD98nPt10baDOKLtIGi47c6rIBI5RypniA3zMP9_4InoaLru9wrMF8vU-nxww2aCY2FNU42y3yU7q63HQXa8fWEB9jhj212G2CetPAEkVT_x86Z9q23-iwbbpz2gb82eueTp1-KKy4YYMXJgEFXp-GFIXnAe0HmLYUkNo_IGcn7z-_W7LUwYE5qfTATIzImITXrow-amuU0c6paKN2hQsaa2GzEmK0ILkUDuiIjiIXECVG2CiFeEiOWvhzHhNauVy4vLTYsVeWllsjuLVSS29NqIRaEDl7rXZJ3hy7bHyv86SCOju7RmfXydkL8npntpn0Pa4yqPYhUQ_jwUqcuqDU4grblzN-apjF6FnThm7b11wBldIYrS7IowlPu88RBTCKXJULUh4gbXcDKoQfjrTr1agUrisUPNRP_uObn5KbHCs-xkT1Z-RoON-G58DDBvtinGm_AFQ1LGI
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagHIADKu-FAkbiakhix3GObUW1QLsH1ErlZMWv7kokWTVZ1P49fhkzeSy7CNQDt0jOOI8Ze76xZr4h5B13PtgoKCZExpko8owZ7yLmE2Glc9bGKdY7n8zk9Ex8Pk_PN2phMK0SY-jQE0V0ezUubjyMHlPiPiSxRCCMdSYJxnixhCDlNrmTgvPF9g3Rt-nvc5aIi7TbkFGKodhYyPOvmbZc1BaB6d9g6J_ZlBvu6WiXPBhwJd3vDeEhueWrR-T-BtvgY_LzoK48LTvWRVpi1ZGdX5cghFzOFE_wG-bg3h_eUX9VNzWOlZiw93W2z8BDM76kSMdZrRCg0vn1sr5aWLaAABlT7KnBdhPUFSXsUXRoAETHVNvqgrarsr6klcfPXjS0b_VDYcv1S7woBkuBxw9DksJ8gPvBTisKpto8IWdHH08Pp2xo4cCskKplRQgImbhTNgsuKFPIQlkrgwnKptYrLIaNMgjSvEgEt4BHVOAxhzAxgKfk_CnZqeDnPCc0tzG3cWawZa_ITGIKnhgjlHCm8DmXEyJGrWk78Jtjm43vOh5oUEdla1S2HpQ9Ie_XYsue4OMmgXzTJHTbnayEvg2K5jfIvh3tR8MyRs0Wla9XjU4kYCmF4eqEPOvtaf06PAVIEctsQrItS1vfgBTh2yPVYt5RhascGQ_Vi_945zfk7vT05Fgff5p9eUnuJVj-0WWt75Gd9nLlXwEoa83rbtX9ApnfL9Y
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JjtQwELVgkBAcEDvNaiSuhiR2HOc4LK1mayHESHCy4m26JbJokkYzv8eXUZWl6UagOXCL5JSzVNn1yqp6Rcgz7nywUVBMiIwzUeQZM95FzCfCSuesjVOsd_64lIsj8e5rOmUTtmNaJcbQYSCK6PdqXNyNC1NG3IskloiDscwkwRAvlhCjXCSXUgW-Hkw6-rb4fcwScZH2-zFKMRSb6nj-NdOeh9rjL_0bCv0zmXLHO82vk2sjrKSHgx3cIBd8dZNc3SEbvEV-vqwrT8uedJGWWHRkV2clCCGVM8UD_JY5uPeHd9Sf1m2NYyXm631eHjJw0Iw3FNk4qw3iU7o6a-rTtWVriI8xw54a7DZBXVHCFkXH_j90yrStjmm3KesTWnn87HVLh04_FHZc3-BFMRoKPH4ckhTmA9gPZlpRsNT2Njmav_nyasHGDg7MCqk6VoSAiIk7ZbPggjKFLJS1MpigbGq9wlrYKIMYzYtEcAtwRAUec4gSAzhKzu-Qgwp-zj1CcxtzG2cGO_aKzCSm4IkxQglnCp9zOSNi0pq2I705dtn4ruORBXVStkZl61HZM_J8K9YM_B7nCeS7JqG7_mAlDF1QND9H9ulkPxpWMWq2qHy9aXUiAUopjFZn5O5gT9vX4SkgilhmM5LtWdr2BmQI3x-p1queKVzlSHio7v_HOz8hlz-9nusPb5fvH5ArCRZ_9DnrD8lBd7LxjwCSdeZxv-h-AaoxLwg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bone+marrow+mesenchymal+stem+cells-derived+exosomal+microRNA-124-3p+attenuates+hypoxic-ischemic+brain+damage+through+depressing+tumor+necrosis+factor+receptor+associated+factor+6+in+newborn+rats&rft.jtitle=Bioengineered&rft.au=Min%2C+Weijie&rft.au=Wu%2C+Yina&rft.au=Fang%2C+Yibin&rft.au=Hong%2C+Bo&rft.date=2022-02-01&rft.eissn=2165-5987&rft.volume=13&rft.issue=2&rft.spage=3194&rft_id=info:doi/10.1080%2F21655979.2021.2016094&rft_id=info%3Apmid%2F35067167&rft.externalDocID=35067167
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-5979&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-5979&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-5979&client=summon